| Literature DB >> 23940794 |
Hui Chen1, Nizhou Liu, Xinchen Xu, Xinhua Qu, Eryi Lu.
Abstract
BACKGROUND: There are conflicting reports as to the association between smoking, radiotherapy, diabetes and osteoporosis and the risk of dental implant failure. We undertook a meta-analysis to evaluate the association between smoking, radiotherapy, diabetes and osteoporosis and the risk of dental implant failure.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23940794 PMCID: PMC3733795 DOI: 10.1371/journal.pone.0071955
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Criteria of Quality Assessment (a Modified McHarm checklist).
| ITEMS | YES | NO/Not sure | |
|
|
|
|
|
| (In present study, we defined “harms” as the totality of adverse consequences of an implant surgery) | |||
|
|
|
|
|
| (In present study, we defined complications that didn't lead to IMPLANT LOSS or IMPLANT REMOVAL as SERIOUS events, e.g. sensitivity on function, radiographic bone loss ≤4 mm or 1/2 of the implant body, probing depth ≤7 mm, etc. | |||
|
|
|
|
|
|
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Figure 1Flow Diagram of Screened and Included Papers.
Study Characteristics (SMOKING).
| Author (Year) | Country | Study | Follow-up | Patient Characteristics | Smoking | Implant Characteristics | QS | ||||
| Mean Age | CON/STY | F | CON/STY | Position (Mand./Max.) | FC/FS | ||||||
| Bain , 1993 | Canada | Retro | 37.88 m | 54.7 yr | NA/NA | 311 | NA | 1,804/390 | 1,115/1,079 | 86/44 | 8 |
| De Bruyn, 1994 | Belgium | Retro | NA | (20–80 yr) | 91/26 | 66 | NA | 338/114 | 208/244 | 5/10 | 8 |
| Gorman, 1994 | USA | Prospec | NA | NA | 228/82 | NA | NA | 142/646 | NA | 47/42 | 7 |
| Bain, 1996 | Canada | Prospec | NA | NA | NA/NA | NA | NA | 176/47 | NA | 10/9 | 8 |
| Minsk, 1996 | USA | Retro | 6 yr | NA | NA/NA | NA | 20 per day | 570/157 | 358/369 | 52/17 | 9 |
| Lindquist, 1997 | Sweden | Prospec | 10 yr | (33–64 yr) | 24/21 | 32 | NA | 139/125 | Mandible | 3/0 | 8 |
| De Bruyn, 1999 | Belgium | Prospec | 7 yrs | NA | 13/10 | NA | 13.2 per day | 32/30 | Maxilla | 9/6 | 10 |
| Grunder, 1999 | Switzerland | Prospec | 34.4 m | 58±15 yr | 55/19 | 34 | NA | 164/55 | NA | 3/0 | 9 |
| Jones, 1999 | USA | Retro | 58 m | 50 yr | 44/19 | 40 | NA | 217/126 | 204/147 | 5/11 | 8 |
| Keller, 1999 | USA | Retro | 12 yr | (15–73 yr) | 26/28 | NA | NA | 143/105 | Grafted maxilla sinus | 26/7 | 10 |
| Lambert, 2000 | USA | Prospec | 3 yr | NA | NA/NA | NA | NA | 1,928/959 | 1616/1271 | 115/85 | 8 |
| Olson, 2000 | USA | Prospec | 38±15 m | 56±12 yr | NA/NA | 1 | NA | 65/51 | Grafted maxillary sinus | 1/2 | 7 |
| Wallace, 2000 | USA | Retro | 4 yr | NA | 39/17 | 27 | NA | 115/72 | NA | 8/12 | 7 |
| Schwartz-Ara, 1999 | Israel | Prospec | 5 yr | 47 yr | NA/NA | 27 | NA | 50/6 | 39/17 | 5/1 | 7 |
| Geurs, 2001 | USA | Retro | 3.2±1.3 yr | NA | NA/NA | NA | NA | 267/62 | Grafted maxilla sinus | 13/7 | 6 |
| Widmark, 20001 | Sweden | Prospec | (3–5 yr) | NA | 25/11 | NA | ≥half a pack a day | 131/67 | Local: 120/Grafted: 101 | 14/26 | 10 |
| Kumar, 2002 | USA | Prospec | NA | NA | 389/72 | NA | NA | 914/269 | 357/826 | 8/15 | 5 |
| Van Steenberghe, 2002 | Belgium | Prospec | NA | 50±14 yr | NA/NA | 243 | NA | 1,107/156 | NA | 19/8 | 7 |
| Karoussis, 2003 | Switzerland | Prospec | 10 yr | NA | 41/12 | NA | NA | 84/28 | NA | 3/2 | 10 |
| DeLuca, 2006 | Canada | Retro | 59.8 m | 49.3 yr | 285/104 | 283 | NA | 1,045/4,94 | NA | 32/26 | 9 |
| Peleg, 2006 | USA | Prospec | 69 m | NA | 505/226 | 453 | NA | 1,505/627 | Maxilla sinus grafting | 28/16 | 7 |
| Mundt, 2006 | Germany | Retro | 88.2 m | 54.1 yr | NA/NA | 94 | NA | 294/363 | 296/367 | 6/30 | 8 |
| Alsaadi, 2008 | Belgium | Retro | 2 yr | NA | 351/61 | 240 | NA | 1,291/223 | 698/816 | 80/21 | 8 |
| Balshe, 2008 | USA | Retro | 5 yr | 49.4 yr | 1299/119 | 861 | 17.7±7 per day | 3,841/766 | 2,633/1974 | 188/77 | 7 |
| Levin, 2008 | Israel | Prospec | 6.14 yr | 45 yr | 54/10 | 40 | NA | 54/10 | NA | 3/1 | 7 |
| Tawil, 2008 | Lebanon | Prospec | 42.4 m | NA | 50/40 | 33 | NA | 254/245 | NA | 2/5 | 9 |
| Anner, 2010 | Isreal | Retro | 31±28 m | 52±12 yrs | 412/63 | 299 | NA | 1,400/226 | NA | 56/21 | 7 |
| Cavalcanti, 2011 | Italy | Retro | 5 yr | 50 yrs | 1019/458 | 1025 | NA | 3,882/1,961 | NA | 112/107 | 9 |
| Conrad, 2011 | USA | Retro | 35.7 m | 55.3 yr | NA/NA | 168 | NA | 446/48 | Maxilla | 28/6 | 8 |
| Rodriguez, 2011 | Spain | Retro | ≥6 m | 53±13 yr | 182/113 | 188 | NA | 644/389 | NA | 18/14 | 9 |
| Vandeweghe, 2011 | Belgium | Retro | 22 m | 54±13.4 yr | 288/41 | 43 | NA | 608/104 | NA | 7/5 | 9 |
| Lin, 2012 | USA | Retro | 12 m | 59.6 yr | 47/28 | 186 | NA | 93/62 | Grafted maxiila sinus | 12/13 | 9 |
| Vervaeke, 2012 | Belgium | Retro | 31±7.2 m | 56±12 yr | 235/60 | 168 | NA | 244/849 | 458/648 | 11/8 | 10 |
CON = control group, that is non-smoking group;STY = study group, that is smoking group; F = Female; Mand. = mandible; Max. = maxilla; Retro = retrospective study; Prospec = prospective study; yr = year; m = month; NA = not available; Local = local bone; Grafted = grafted bone; FC = failure implant number of Control Group; FS = failure implant number of Study Group; QS = quality assessment score.
Study Characteristics (OSTEOPOROSIS).
| Author (Year) | Country | Study | Follow-up | Patient Characteristics | Implant Characteristics | QS | ||||
| Mean Age | CON/STY | F | CON/STY | Position (Mand./Max.) | FC/FS | |||||
| Amorim,2007 | Brazil | Retro | 9 m | 58.2 yr | 20/19 | 39 | 43/39 | Mandible | 0/1 | 8 |
| Alsaadi,2008 | Belgium | Retro | 2 yr | NA | 393/19 | 240 | 1,446/68 | 698/816 | 92/9 | 8 |
| Holahan,2008 | USA | Retro | 5.4 yr | 63±9 yr | 564/192 | 746 | 306/340 | 378/268 | 17/20 | 7 |
| Dvorak,2011 | Austria | Retro | 6±4 yr | ≥45 yr | 115/62 | 117 | 543/258 | 396/432 | 17/20 | 7 |
CON = control group, that is non-osteoporosis group; STY = study group, that is osteoporosis group; F = Female; Mand. = mandible; Max. = maxilla; Retro = retrospective study; Prospec = prospective study; yr = year; m = month; NA = not available; Local = local bone; Grafted = grafted bone; FC = failure implant number of Control Group; FS = failure implant number of Study Group; QS = quality assessment score.
Figure 2Forest plot of studies with dental implant failure risk for smoking versus non-smoking patients.
The combined Relative risks (RR) and 95% confidence intervals (CIs) were calculated using the random-effects model.
Subgroup analysis to investigate differences between studies included in meta-analysis.
| Subgroup | No. of Studies | RR (95% CI) |
|
|
|
|
| |||||
|
| |||||
| Prospective | 15 | 1.34(0.90,2.00) | 67 | <0.0001 | 0.06 |
| Retrospective | 18 | 2.01(1.75,2.30) | 14 | 0.29 | |
|
| |||||
| United States | 13 | 1.59 (1.27,1.98) | 46 | 0.04 | 0.08 |
| Europe | 13 | 2.18 (1.56,3.05) | 56 | 0.007 | |
| Other Regions | 7 | 2.23 (1.77,2.81) | 0 | 0.90 | |
|
| |||||
| ≥5 | 11 | 1.72 (1.37,2.15) | 28 | 0.18 | 0.32 |
| <5 | 17 | 1.98 (1.68,2.33) | 14 | 0.29 | |
|
| |||||
| <500 | 16 | 2.25 (1.64,3.08) | 25 | 0.17 | 0.23 |
| ≥500 | 17 | 1.81 (1.56,2.11) | 40 | 0.05 | |
|
| |||||
| <55 | 11 | 2.15 (1.87,2.47) | 0 | 0.67 | 0.23 |
| ≥55 | 6 | 1.67 (1.13,2.47) | 0 | 0.54 | |
|
| |||||
|
| |||||
| Prospective | 6 | 2.02 (1.37,2.97) | 0 | 0.73 | 0.58 |
| Retrospective | 10 | 2.50 (1.32,4.75) | 81 | <0.00001 | |
|
| |||||
| United States | 2 | 1.46 (0.12,17.16) | 69 | 0.07 | 0.72 |
| Europe | 14 | 2.29 (1.45,3.63) | 71 | <0.0001 | |
|
| |||||
| ≥5 | 5 | 1.62 (0.85,3.11) | 62 | 0.03 | 0.83 |
| <5 | 8 | 1.76 (1.20,2.59) | 20 | 0.27 | |
|
| |||||
| <250 | 10 | 2.14 (1.27,3.60) | 64 | 0.003 | 0.56 |
| ≥250 | 6 | 2.74 (1.43,5.25) | 76 | 0.001 | |
|
| |||||
| <60 | 8 | 1.95 (1.11,3.42) | 78 | <0.0001 | 0.68 |
| ≥60 | 3 | 1.40 (0.33,5.97) | 0 | 0.69 | |
Figure 3Forest plot of studies with dental implant failure risk for patients with radiotherapy versus non-smoking.
The combined Relative risks (RR) and 95% confidence intervals (CIs) were calculated using the random-effects model.
Figure 4Forest plot of studies with dental implant failure risk for patients with diabetes versus non-diabetes.
The combined Relative risks (RR) and 95% confidence intervals (CIs) were calculated using the random-effects model.
Figure 5Forest plot of studies with dental implant failure risk for patients with osteoporosis versus non-osteoporosis.
The combined Relative risks (RR) and 95% confidence intervals (CIs) were calculated using the random-effects model.
Study Characteristics (RADIOTHERAPY).
| Author (Year) | Country | Study | Follow-up | Patient Characteristics | Radiotherapy | Implant Characteristics | QS | |||||
| Mean Age | CON/STY | F | Time | Dose (Gy) | CON/STY | Position (Mand./Max.) | FC/FS | |||||
| Esser, 1997 | Germany | Prospec | NA | (37–79 yr) | NA/NA | 9 | BP | 60 | 66/152 | Mandible | 7/33 | 7 |
| Werkmeister, 1999 | Germany | Retro | 3 yrs | 55 yr | 17/12 | 6 | BP | 54 | 79/30 | Local: 64/Grafted: 45 | 19/8 | 7 |
| Keller, 1999 | USA | Retro | 12 yrs | (15–73 yr) | 52/2 | NA | NA | 55 and 61 | 237/11 | Grafted maxilla | 33/0 | 10 |
| Shaw, 2005 | UK | Retro | 3.5 yr | 58 yr | 43/34 | 32 | BP | 40–66 | 192/172 | Local: 238/Grafted: 126 | 25/31 | 9 |
| Yerit, 2006 | Austria | Prospec | 5.4±3.2 yr | 58±14 yr | NA/NA | 15 | BP | 50 | 162/154 | Local: 238/Grafted: 78 | 15/29 | 9 |
| Schepers, 2006 | Netherlands | Retro | up to 23 m | 66.11 yr | 27/21 | 19 | AP | 60–68 | 78/61 | NA | 0/2 | 8 |
| Landes, 2006 | Germany | Prospec | 36 m | 63 yr | 11/19 | 8 | BP | 57 | 42/72 | NA | 0/1 | 8 |
| Nelson, 2007 | Germany | Prospec | 10.3 yr | 59 yr | NA/29 | 30 | BP | up to 72 | 311/124 | 281/154 | 4/7 | 7 |
| Alsaadi, 2008 | Belgium | Retro | 2 yr | NA | 410/2 | 240 | NA | NA | 1,499/15 | 698/816 | 98/3 | 8 |
| Schoen, 2008 | Netherlands | Prospec | 12 m | 62±11 yr | 16/19 | 15 | AP | 60.1±7.7 | 64/76 | Local bone | 2/2 | 9 |
| Klein, 2009 | Germany | Retro | 5 yr | 58.4 yr | 16/27 | 12 | BP | <50 or ≥50 | 74/116 | Local: 62/Grafted: 128 | 12/13 | 8 |
| Cuesta-Gil, 2009 | Spain | Prospec | / | 52 yr | 32/79 | 31 | Mixed | 50–60 | 311/395 | Local: 454/Grafted: 252 | 6/75 | 9 |
| Salinas, 2010 | USA | Retro | 41.1 | NA | 18/26 | 19 | Mixed | > 60 | 116/90 | Local: 105/Flap: 114 | 8/23 | 10 |
| Linsen, 2012 | Germany | Prospec | 48±34.3 m | 56±16 yr | 32/34 | 23 | BP | 36 or 60 | 135/127 | 213/49 | 6/8 | 10 |
| Jacobsen, 2012 | Switzerland | Retro | 67 m | 52.4 yr | NA/NA | 16 | AP | NA | 93/47 | Local: 41/Flap: 99 | 14/14 | 9 |
| Fenlon, 2012 | UK | Retro | / | NA | 29/12 | NA | AP | 66 | 110/35 | Grafted bone | 3/15 | 8 |
CON = control group,that is non-radiotherapy group; STY = study group, that is radiotherapy group; F = Female; BP = before placement; AP = after placement; Mand. = mandible; Max. = maxilla; Retro = retrospective study; Prospec = prospective study; yr = year; m = month; NA = not available,; Local = local bone; Grafted = grafted bone; FC = failure implant number of Control Group; FS = failure implant number of Study Group; QS = quality assessment score.
Study Characteristics (DIABETES).
| Author (Year) | Country | Study | Follow-up | Patient Characteristics | Diabetes Type | Implant Characteristics | QS | ||||
| Mean Age | CON/STY | F | CON/STY | Position (Mand./Max.) | FC/FS | ||||||
| Keller, 1999 | USA | Prosp | 12 yrs | (15–73 yr) | 52/2 | NA | NA | 237/11 | Grafted maxilla | 0/0 | 10 |
| Morris, 2000 | New Zealand | Prosp | 36 m | NA | 408/255 | NA | II | 2632/255 | Mixed | 180/20 | 7 |
| Tawil, 2008 | Lebanon | Retro | 42.4 m | 62.15 yr | 45/45 | 33F | II | 244/255 | Mixed | 2/7 | 9 |
| Alsaadi, 2008 | Belgium | Retro | 2 yr | NA | 402/10 | 240 | I:1 II:9 | 1,480/34 | 698/816 | 202/0 | 8 |
| Anner, 2010 | Isreal | Prosp | 31±28 m | 52±12 yr | 426/49 | 299 | NA | 1,449/177 | Mixed | 72/5 | 7 |
CON = control group, that is non-diabetes group; STY = study group, that is diabetes group; F = Female; Mand. = mandible; Max. = maxilla; Retro = retrospective study; Prospec = prospective study; yr = year; m = month; NA = not available; Local = local bone; Grafted = grafted bone; FC = failure implant number of Control Group; FS = failure implant number of Study Group; QS = quality assessment score.